PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1774904
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1774904
Global HEOR Services Market to Reach US$2.5 Billion by 2030
The global market for HEOR Services estimated at US$1.3 Billion in the year 2024, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2024-2030. Economic Modelling / Evaluation Service, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$915.6 Million by the end of the analysis period. Growth in the Real-World Data Analysis & Information Systems Service segment is estimated at 13.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$343.5 Million While China is Forecast to Grow at 16.2% CAGR
The HEOR Services market in the U.S. is estimated at US$343.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$521.1 Million by the year 2030 trailing a CAGR of 16.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.
Health Economics and Outcomes Research (HEOR) services have become a critical component of healthcare decision-making, helping pharmaceutical companies, payers, and regulatory bodies assess the economic value and real-world impact of medical treatments. These services provide data-driven insights on the cost-effectiveness, safety, and quality of healthcare interventions, ensuring that stakeholders make informed reimbursement and pricing decisions. With rising healthcare costs and the growing emphasis on value-based care, HEOR services play a crucial role in determining drug pricing strategies, formulary placements, and patient access programs. Additionally, regulatory agencies such as the FDA and EMA are increasingly relying on HEOR data to evaluate new drug approvals and post-market surveillance. As healthcare systems shift toward evidence-based medicine, the demand for HEOR services continues to grow.
Technological advancements, including artificial intelligence, big data analytics, and real-world evidence (RWE) platforms, are transforming the HEOR landscape. AI-driven predictive modeling is enabling more accurate forecasting of treatment outcomes and cost-effectiveness. The integration of electronic health records (EHRs) and wearable device data is improving real-world evidence generation, allowing for more comprehensive health outcome assessments. Blockchain technology is also being explored to enhance data security and transparency in HEOR studies. Additionally, advancements in health informatics are enabling faster and more efficient data processing, reducing the time required to generate insights for healthcare decision-making. These innovations are making HEOR services more precise, scalable, and impactful in guiding healthcare policy and investment decisions.
Pharmaceutical companies are increasingly relying on HEOR services to navigate complex pricing and reimbursement landscapes, optimize market access strategies, and demonstrate the value of their products to healthcare payers. The growing emphasis on personalized medicine and specialty drugs has heightened the need for robust health economic assessments, ensuring that innovative therapies remain accessible and affordable. Additionally, HEOR services are becoming essential in conducting comparative effectiveness research, helping pharmaceutical firms differentiate their products from competitors. The expansion of biosimilars and gene therapies has further increased the need for HEOR-driven evaluations, as companies seek to justify premium pricing models. These factors are driving substantial growth in the HEOR services market.
The growth in the HEOR services market is driven by rising healthcare expenditures, increasing regulatory requirements for real-world evidence, and advancements in data analytics. The transition toward value-based healthcare models has amplified the demand for economic and outcomes research, ensuring that treatments provide both clinical and financial benefits. Additionally, the expansion of healthcare infrastructure in emerging markets is creating new opportunities for HEOR service providers, as governments seek to optimize healthcare spending. The growing number of clinical trials and the need for post-market surveillance are further fueling market expansion. As healthcare systems become more data-driven, HEOR services will continue to play a pivotal role in shaping drug development, pricing, and reimbursement strategies.
SCOPE OF STUDY:
The report analyzes the HEOR Services market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Service (Economic Modelling / Evaluation Service, Real-World Data Analysis & Information Systems Service, Clinical Outcome Service, Market Access Solutions & Reimbursement Service, Other Services); Service Provider (Consultancy Service Provider, Contract Research Organizations Service Provider); End-Use (Healthcare Providers End-Use, Healthcare Payers End-Use, Biotech / Pharma Companies End-Use, Government Organizations End-Use, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 44 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.